收养一名孤儿。
Adopting an orphan.
作者信息
Rinaldi Andrea
出版信息
EMBO Rep. 2005 Jun;6(6):507-10. doi: 10.1038/sj.embor.7400450.
Abstract
Incentives to develop drugs for rare disorders raise hopes and controversy
摘要
开发罕见病药物的激励措施引发了希望与争议
相似文献
1
Adopting an orphan.收养一名孤儿。
EMBO Rep. 2005 Jun;6(6):507-10. doi: 10.1038/sj.embor.7400450.
2
Confusion over Article 8.对第8条的困惑。
EMBO Rep. 2005 Aug;6(8):690. doi: 10.1038/sj.embor.7400485.
3
Regulators adopt more orphan drugs.监管机构批准了更多孤儿药。
Nature. 2014 Apr 3;508(7494):16-7. doi: 10.1038/508016a.
4
Rare disease resources not as rare as one might think.
Am J Health Syst Pharm. 2013 Jun 15;70(12):1013-4. doi: 10.2146/ajhp130071.
5
The challenges of orphan drugs and orphan diseases: real and imagined.孤儿药和孤儿病面临的挑战：真实与想象。
Clin Pharmacol Ther. 2012 Aug;92(2):151-3. doi: 10.1038/clpt.2012.72.
6
Time to revisit the orphan drug law.是时候重新审视孤儿药法案了。
Eur J Clin Pharmacol. 2012 Feb;68(2):113. doi: 10.1007/s00228-011-1115-3. Epub 2011 Aug 13.
7
Policy alternatives for treatments for rare diseases.罕见病治疗的政策选择。
CMAJ. 2010 Nov 23;182(17):E787-92. doi: 10.1503/cmaj.081429. Epub 2010 Jul 12.
8
Should off-label drug use be off-the-table?药品的非适应症用药是否应被排除在外？
J Pediatr Endocrinol Metab. 2007 Feb;20(2):171-2.
9
Orphan drugs revisited.孤儿药再探讨。
QJM. 2006 May;99(5):341-5; discussion 350-1. doi: 10.1093/qjmed/hcl033. Epub 2006 Feb 27.
10
Does orphan drug legislation really answer the needs of patients?孤儿药立法真的能满足患者的需求吗？
Lancet. 2008 Jun 14;371(9629):2041-4. doi: 10.1016/S0140-6736(08)60873-9.
引用本文的文献
1
Between hope and reality: treatment of genetic diseases through nucleic acid-based drugs.在希望与现实之间：通过核酸药物治疗遗传疾病
Commun Biol. 2024 Apr 23;7(1):489. doi: 10.1038/s42003-024-06121-9.
2
Cross-national comparative study of orphan drug policies in Saudi Arabia, the United States, and the European Union.沙特阿拉伯、美国和欧盟孤儿药政策的跨国比较研究。
Saudi Pharm J. 2023 Sep;31(9):101738. doi: 10.1016/j.jsps.2023.101738. Epub 2023 Aug 9.
3
Voluntariness or legal obligation? An ethical analysis of two instruments for fairer global access to COVID-19 vaccines.自愿还是法律义务？对实现更公平获取 COVID-19 疫苗的两种工具的伦理分析。
Front Public Health. 2023 Jan 26;11:995683. doi: 10.3389/fpubh.2023.995683. eCollection 2023.
4
The definition of rare disease in China and its prospects.中国罕见病的定义及其前景。
Intractable Rare Dis Res. 2022 Feb;11(1):29-30. doi: 10.5582/irdr.2022.01034.
5
The urgent need to empower rare disease organizations in China: an interview-based study.中国迫切需要增强罕见病组织的能力：一项基于访谈的研究。
Orphanet J Rare Dis. 2020 Oct 12;15(1):282. doi: 10.1186/s13023-020-01568-5.
6
Orphan drug development: the increasing role of clinical pharmacology.孤儿药开发：临床药理学的作用日益凸显。
J Pharmacokinet Pharmacodyn. 2019 Oct;46(5):395-409. doi: 10.1007/s10928-019-09646-3. Epub 2019 Jul 23.
7
Rare diseases in China: analysis of 2014-2015 hospitalization summary reports for 281 rare diseases from 96 tertiary hospitals.中国罕见病：96 家三甲医院 281 种罕见病 2014-2015 年住院汇总分析报告
Orphanet J Rare Dis. 2019 Jul 1;14(1):160. doi: 10.1186/s13023-019-1137-y.
8
The quality of economic evaluations of ultra-orphan drugs in Europe - a systematic review.欧洲超罕见病药物经济评估的质量——一项系统评价
Orphanet J Rare Dis. 2015 Jul 30;10:92. doi: 10.1186/s13023-015-0305-y.
9
Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.用于鉴定治疗脑海绵状血管畸形的药物新用途的策略。
Circulation. 2015 Jan 20;131(3):289-99. doi: 10.1161/CIRCULATIONAHA.114.010403. Epub 2014 Dec 8.
10
Study and analysis of the state of rare disease research in Shandong Province, China.中国山东省罕见病研究状况的研究与分析。
Intractable Rare Dis Res. 2012 Nov;1(4):161-6. doi: 10.5582/irdr.2012.v1.4.161.
本文引用的文献
1
Rare essentials: drugs for rare diseases as essential medicines.罕见病基本药物：作为基本药物的罕见病用药
Bull World Health Organ. 2006 Sep;84(9):745-51. doi: 10.2471/blt.06.031518.
2
The orphan drug backlash.孤儿药的强烈反对。
Sci Am. 2003 May;288(5):80-7. doi: 10.1038/scientificamerican0503-80.
3
Two decades of orphan product development.二十年的孤儿药产品研发。
Nat Rev Drug Discov. 2002 Oct;1(10):821-5. doi: 10.1038/nrd919.
Zotero 插件